title: Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults.
abstract: Prevention of respiratory syncytial virus (RSV) illness in infants is a major public health priority, but there is no approved vaccine. Palivizumab is a monoclonal antibody that provides RSV prophylaxis but requires 5 monthly injections and is approved only for infants who experience the greatest morbidity and mortality from RSV. Thus, there remains a significant unmet medical need for prevention of RSV disease in healthy infants. MEDI8897 is a recombinant human RSV monoclonal antibody with a modified Fc region that extends its half-life and is being developed as RSV prophylaxis for all infants. In this phase 1, first-in-human, placebo-controlled study, 136 healthy adults were randomized to receive a single dose of MEDI8897 (n= 102) or placebo (n= 34) in 1 of 5 cohorts (300, 1,000, or 3,000 mg intravenously or 100 or 300 mg intramuscularly [i.m.]) and were monitored for 360 days. The mean half-life of MEDI8897 was 85 to 117 days across dose groups, and bioavailability after 300-mg i.m. dose administration was 77%. Time to maximum concentration following i.m. dosing was 5 to 9 days. Antidrug antibody (ADA) responses were detected in a similar proportion of placebo (15.2%) and MEDI8897 (13.7%) recipients. The safety profile of MEDI8897 was similar to that of the placebo. These results support clinical studies of the i.m. administration of a single dose of MEDI8897 in the target population of infants to provide protection for the duration of the RSV season. (This study has been registered at ClinicalTrials.gov under identifier NCT02114268.).
authors.affiliation: MedImmune (AstraZeneca), Gaithersburg, Maryland, USA griffinp@medimmune.com.
authors.forename: M Pamela
authors.initials: MP
authors.lastname: Griffin
authors.affiliation: MedImmune (AstraZeneca), Gaithersburg, Maryland, USA.
authors.forename: Anis A
authors.initials: AA
authors.lastname: Khan
authors.affiliation: MedImmune (AstraZeneca), Gaithersburg, Maryland, USA.
authors.forename: Mark T
authors.initials: MT
authors.lastname: Esser
authors.affiliation: MedImmune (AstraZeneca), Gaithersburg, Maryland, USA.
authors.forename: Kathryn
authors.initials: K
authors.lastname: Jensen
authors.affiliation: MedImmune (AstraZeneca), Gaithersburg, Maryland, USA.
authors.forename: Therese
authors.initials: T
authors.lastname: Takas
authors.affiliation: Vince and Associates Clinical Research, Overland Park, Kansas, USA.
authors.forename: Martin K
authors.initials: MK
authors.lastname: Kankam
authors.affiliation: MedImmune (AstraZeneca), Gaithersburg, Maryland, USA.
authors.forename: Tonya
authors.initials: T
authors.lastname: Villafana
authors.affiliation: MedImmune (AstraZeneca), Gaithersburg, Maryland, USA.
authors.forename: Filip
authors.initials: F
authors.lastname: Dubovsky
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000097:blood / Q000493:pharmacokinetics*; D000914:Antibodies, Viral / Q000097:blood / Q000494:pharmacology*; D000998:Antiviral Agents / Q000097:blood / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001682:Biological Availability; D015992:Body Mass Index; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D064368:Healthy Volunteers; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008297:Male; D061214:Patient Safety; D011322:Primary Prevention; D018357:Respiratory Syncytial Virus Infections / Q000276:immunology / Q000517:prevention & control*; D018113:Respiratory Syncytial Virus, Human / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D000998:Antiviral Agents
keywords: MEDI8897; RSV; healthy adults; infants; lower respiratory tract infections; pharmacokinetics; respiratory syncytial virus